Suivre
Elsa Curtit
Elsa Curtit
Besançon France
Adresse e-mail validée de univ-fcomte.fr
Titre
Citée par
Citée par
Année
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis
E Curtit, V Nerich, L Mansi, L Chaigneau, L Cals, C Villanueva, F Bazan, ...
The oncologist 18 (6), 667-674, 2013
1072013
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityImmune-Mediated Antitumor Efficacy of Rapalogs
L Beziaud, L Mansi, P Ravel, EL Marie-Joseph, C Laheurte, L Rangan, ...
Cancer Research 76 (14), 4100-4112, 2016
572016
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
E Curtit, A Thiery-Vuillemin, T Nguyen, B Heyd, X Pivot, V Di Martino, ...
Journal of clinical oncology: official journal of the American Society of …, 2011
502011
Interaction between phytotherapy and oral anticancer agents: prospective study and literature review
AL Clairet, M Boiteux-Jurain, E Curtit, M Jeannin, B Gérard, V Nerich, ...
Medical Oncology 36 (5), 1-18, 2019
402019
A randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects
X Pivot, E Curtit, YJ Lee, G Golor, A Gauliard, D Shin, Y Kim, H Kim, ...
Clinical Therapeutics 38 (7), 1665-1673. e3, 2016
362016
Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay
E Curtit, L Mansi, Y Maisonnette-Escot, JL Sautière, X Pivot
European Journal of Surgical Oncology (EJSO) 43 (5), 921-930, 2017
242017
Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer
A Thiery-Vuillemin, E Curtit, T Maurina, D Montange, C Succi, T Nguyen, ...
Annals of oncology 23 (11), 2992-2993, 2012
232012
Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer
F Calcagno, T Nguyen, E Dobi, C Villanueva, E Curtit, S Kim, ...
Clinical Medicine Insights: Oncology 7, CMO. S7256, 2013
222013
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma …
S Kim, E Dobi, M Jary, F Monnien, E Curtit, T NGuyen, Z Lakkis, B Heyd, ...
BMC cancer 13 (1), 1-10, 2013
212013
Targeting the RAS signalling pathway in cancer
L Mansi, E Viel, E Curtit, J Medioni, C Le Tourneau
Bulletin Du Cancer 98 (9), 1019-1028, 2011
172011
Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
L Garnier, F Ducray, C Verlut, MI Mihai, F Cattin, A Petit, E Curtit
Frontiers in Oncology 9, 177, 2019
142019
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
DG Cox, E Curtit, G Romieu, P Fumoleau, M Rios, H Bonnefoi, T Bachelot, ...
Oncotarget 7 (47), 77358, 2016
142016
Age, neurological status MRC scale, and postoperative morbidity are prognostic factors in patients with glioblastoma treated by chemoradiotherapy
C Verlut, G Mouillet, E Magnin, J Buffet-Miny, G Viennet, F Cattin, ...
Clinical Medicine Insights: Oncology 10, CMO. S38474, 2016
132016
Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis
A Thiery-Vuillemin, D Montange, E Kalbacher, T Maurina, T Nguyen, ...
Annals of oncology 22 (9), 2152-2154, 2011
132011
Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice
E Curtit, JM Vannetzel, JC Darmon, S Roche, H Bourgeois, S Dewas, ...
The Breast 44, 39-45, 2019
122019
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation
E Curtit, V Benhamo, N Gruel, T Popova, E Manie, P Cottu, O Mariani, ...
Oncotarget 6 (34), 35616, 2015
122015
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
E Curtit, P Nouyrigat, N Dohollou, E Levy, A Lortholary, J Gligorov, ...
European Journal of Cancer 47 (16), 2396-2402, 2011
122011
Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury
E Curtit, L Chaigneau, J Pauchot, T Nguyen, V Nerich, F Bazan, ...
Anticancer research 32 (4), 1481-1483, 2012
112012
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico …
E Curtit, X Pivot, J Henriques, S Paget-Bailly, P Fumoleau, M Rios, ...
Breast Cancer Research 19 (1), 1-9, 2017
102017
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report
G Meynard, L Mansi, P Lebahar, C Villanueva, E Klajer, F Calcagno, ...
Oncology reports 37 (3), 1573-1578, 2017
102017
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20